Atossa Therapeutics Inc (ATOS) FinancialsATOSFinancialAtossa Therapeutics Inc

Evaluating the bottom line, Atossa Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -89.23%, provide a clear picture of how effectively ATOS converts its operational activities into shareholder value.

In the context of the broader market, ATOS competes directly with industry leaders such as TXMD and LTRN. With a market capitalization of $25.95M, it holds a significant position in the sector. When comparing efficiency, ATOS's gross margin of N/A stands against TXMD's N/A and LTRN's N/A. Such benchmarking helps identify whether Atossa Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Atossa has been facing significant financial challenges, with a net income of -$8,491,000 for Q2 2026 and a negative EPS of -0.95, indicating ongoing losses. The current ratio is 5.69, showing a strong liquidity position despite the losses.